Curis, Inc. filed its third-quarter 2026 financial and operating results on November 12, 2026, reporting a net loss of $8.1 million for the period ended September 30, 2026, alongside updates on its two ongoing emavusertib clinical studies.

Key Highlights

  • Net loss of $8.1 million for Q3 2026, or $1.94 per share on both a basic and diluted basis, compared to a net loss of $7.7 million, or $9.86 per share, in Q3 2025.
  • No revenue reported for the quarter ended September 30, 2026, following the sale of Erivedge royalties to Oberland in Q4 2025; revenues were $3.2 million in the same quarter of 2025.
  • Cash and cash equivalents of $5.0 million as of September 30, 2026, with approximately 4.1 million shares of common stock outstanding.
  • 12 patients enrolled in the TakeAim CLL study as of the filing date, with initial data expected in December 2026.
  • TakeAim Lymphoma data (as of July 1, 2026) showed 100% ORR in 5 evaluable BTKi-naive patients and 33% ORR in 10 of 30 evaluable BTKi-experienced patients.
  • Cash runway extended into Q1 2027, according to the company, combining the $5.0 million on hand with approximately $7.5 million in net proceeds from the October 2026 private placement.

Curis Reports Q3 2026 Financials and Emavusertib Study Updates

Curis, Inc. (NASDAQ:CRIS) reported a net loss of $8.1 million, or $1.94 per share, for the third quarter ended September 30, 2026, according to the filing. For the nine months ended September 30, 2026, the company reported a net loss of $40.9 million, or $16.77 per share, compared to a net loss of $26.9 million, or $43.82 per share, for the same period in 2025. The company disclosed no revenue for the quarter, attributing the absence to the prior-year sale of Erivedge royalties to Oberland.

Research and development expenses for Q3 2026 were $5.6 million, down from $6.4 million in Q3 2025. The filing attributed the decrease primarily to lower employee-related costs, partially offset by higher clinical costs. General and administrative expenses were $3.2 million for Q3 2026, compared to $3.7 million in the prior-year period, with the decrease attributed primarily to lower employee-related costs, partially offset by an increase in legal costs. Other income was $0.6 million for Q3 2026, compared to other expense of $0.8 million in Q3 2025, driven primarily by a change in fair value of the warrant liability associated with the January 2026 private placement.

On the clinical side, the filing disclosed that 12 patients have been enrolled in the TakeAim CLL study (CA-4948-203, NCT07271667), with initial data expected in December 2026. In the TakeAim Lymphoma registrational study (CA-4948-101, NCT03328078), updated data reported as of July 1, 2026 showed that among evaluable BTKi-naive patients, 5 of 5 achieved an objective response (100% ORR), while among evaluable BTKi-experienced patients, 10 of 30 achieved an objective response (33% ORR). The filing noted that in 2025, the FDA and EMA provided guidance that the ongoing registrational study could support regulatory applications for accelerated approval in relapsed/refractory PCNSL. The company completed a public offering in August 2026 and a private placement in October 2026, which it said extended its cash runway into 2027.

What Was Disclosed

Curis disclosed Q3 2026 financial results showing a net loss of $8.1 million and cash of $5.0 million, along with clinical updates on two ongoing emavusertib studies and the company's expectation that combined cash resources will fund operations into Q1 2027.